What low back pain is and why we need to pay attention

…, S Genevay, D Hoy, J Karppinen, G Pransky, J Sieper… - The Lancet, 2018 - thelancet.com
Low back pain is a very common symptom. It occurs in high-income, middle-income, and low-income
countries and all age groups from children to the elderly population. Globally, years …

The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general

…, R Valle-Oñate, U Weber, J Wei, J Sieper - Annals of the …, 2011 - ard.bmj.com
Objective To evaluate new classification criteria for peripheral spondyloarthritis (SpA) in
patients with SpA with peripheral manifestations only. Methods In this Assessment of …

Prevention and treatment of low back pain: evidence, challenges, and promising directions

…, B Öberg, WC Peul, G Pransky, M Schoene, J Sieper… - The Lancet, 2018 - thelancet.com
Many clinical practice guidelines recommend similar approaches for the assessment and
management of low back pain. Recommendations include use of a biopsychosocial framework …

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

…, R Valle-Oñate, U Weber, J Wei, J Sieper - Annals of the …, 2009 - ard.bmj.com
Objective: To validate and refine two sets of candidate criteria for the classification/diagnosis
of axial spondyloarthritis (SpA). Methods: All Assessment of SpondyloArthritis international …

The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis

J Sieper, M Rudwaleit, X Baraliakos, J Brandt… - Annals of the …, 2009 - ard.bmj.com
The field of spondyloarthritis (SpA) has experienced major progress in the last decade,
especially with regard to new treatments, earlier diagnosis, imaging technology and a better …

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

…, H Sörensen, H Zeidler, W Thriene, J Sieper - The Lancet, 2002 - thelancet.com
Background Treatment options for patients with ankylosing spondylitis are few. We aimed to
assess the effectiveness of infliximab, an antibody to tumour necrosis factor (TNF)-α, in …

Ankylosing spondylitis

J Braun, J Sieper - The Lancet, 2007 - thelancet.com
Ankylosing spondylitis is a common inflammatory rheumatic disease that affects the axial
skeleton, causing characteristic inflammatory back pain, which can lead to structural and …

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

…, I Olivieri, K Pavelka, J Sieper… - Annals of the …, 2011 - ard.bmj.com
This first update of the ASAS/EULAR recommendations on the management of ankylosing
spondylitis (AS) is based on the original paper, a systematic review of existing …

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

…, J Reveille, M Rudwaleit, J Sieper… - Annals of the …, 2017 - ard.bmj.com
To update and integrate the recommendations for ankylosing spondylitis and the recommendations
for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA…

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis

…, J Sieper, M Dougados, J Davis, J Braun… - Annals of the …, 2009 - ard.bmj.com
Objectives: To develop a new index for disease activity in ankylosing spondylitis (ASDAS)
that is truthful, discriminative and feasible, and includes domains/items that are considered …